HIKMA
● BETARequest early access

von Willebrand Disease Types: A High-Yield USMLE Review

Von Willebrand disease (vWD) is the most common inherited bleeding disorder. Von Willebrand factor (vWF) has two jobs: binding platelets to exposed subendothelium (primary hemostasis) and carrying and stabilizing factor VIII (secondary hemostasis). The disorder is classified by whether the defect is quantitative (too little vWF) or qualitative (dysfunctional vWF), which sorts patients into three types with distinct laboratory profiles and treatments.

Type 1 — Partial Quantitative Deficiency

Type 1 is the most common form, accounting for roughly 70–80% of cases, and is inherited in an autosomal dominant pattern. It is a partial quantitative defect: there is simply less vWF around. vWF level (antigen) is decreased but the vWF that is present functions normally, so vWF activity and antigen fall proportionally; factor VIII is decreased secondarily (since vWF carries and stabilizes it). Disease is usually mild. Importantly, because the deficiency is only partial, factor VIII may remain within the normal range in mild Type 1 — so the PTT can be NORMAL, and a normal PTT does not exclude vWD. DDAVP (desmopressin) is first-line because it releases stored vWF from Weibel-Palade bodies in endothelium — this works well in Type 1, where the problem is quantity rather than quality.

Type 2 — Qualitative Defect

Type 2 makes up about 15–20% of cases and reflects a qualitative problem: the vWF that is present does not work properly. vWF antigen may be normal or only mildly decreased, but vWF function (ristocetin cofactor activity) is disproportionately decreased, giving a low activity-to-antigen ratio. Subtypes have distinct mechanisms: 2A (loss of high-molecular-weight multimers → decreased function), 2B (gain-of-function increasing vWF binding to platelet GpIb, with thrombocytopenia), 2M (decreased function with normal multimers), and 2N (defective vWF binding to factor VIII, so factor VIII is markedly low and mimics hemophilia A). Inheritance is subtype-dependent: 2A, 2B, and 2M are autosomal dominant, but 2N is autosomal recessive — it typically requires two abnormal alleles (homozygous or compound heterozygous) to produce a bleeding phenotype, a classic USMLE distinguishing point. Because the molecule itself is dysfunctional, DDAVP is not reliably effective, and vWF-containing concentrates are often used. A high-yield exception: DDAVP is contraindicated in Type 2B, where a gain-of-function mutation increases vWF binding to platelet GpIb — DDAVP releases abnormal vWF that binds platelets and can precipitate or worsen thrombocytopenia, so it should be avoided rather than merely considered less effective.

Type 3 — Severe Quantitative Deficiency

Type 3 is rare (<5%), autosomal recessive, and the most severe form. It is a severe quantitative defect with essentially absent vWF level and absent vWF function. Because vWF normally carries and stabilizes factor VIII, factor VIII is markedly decreased in Type 3, producing the most pronounced bleeding phenotype, which can include deep bleeding resembling hemophilia in addition to mucocutaneous bleeding. The PTT is reliably prolonged in Type 3 because factor VIII is markedly low. Treatment requires vWF-containing factor VIII concentrates; DDAVP is inadequate because there is little to no stored vWF to release.

Shared Presentation and Laboratory Findings

All types share the mucocutaneous bleeding pattern of a primary hemostasis defect: epistaxis, menorrhagia, GI bleeding, easy bruising, and prolonged bleeding after surgery or dental procedures. Labs classically show a prolonged PTT (from low factor VIII) with normal PT, a prolonged bleeding time or abnormal PFA-100, low vWF antigen and/or vWF activity (ristocetin cofactor), and low factor VIII. However, the PTT is NOT always prolonged — in mild Type 1 vWD factor VIII may stay within the normal range, so the PTT can be normal and a normal PTT does not exclude vWD. When present, the PTT prolongation is most pronounced in Type 3 (and in Type 2N) where factor VIII is markedly reduced. Platelet count is typically normal — an important exception is Type 2B, which can cause thrombocytopenia. On a mixing study, the prolonged PTT of vWD corrects, consistent with a factor deficiency rather than an inhibitor.

High-yield

  • vWF has two roles: platelet adhesion to subendothelium (primary hemostasis) and carrying/stabilizing factor VIII (secondary hemostasis).
  • vWD is the most common inherited bleeding disorder.
  • Type 1 (70–80%) = partial quantitative; Type 2 (15–20%) = qualitative; Type 3 (<5%) = severe quantitative.
  • Inheritance: Type 1 and Type 2 subtypes 2A/2B/2M are autosomal dominant; Type 2N and Type 3 are autosomal recessive.
  • Mucocutaneous bleeding (epistaxis, menorrhagia, GI bleeding) is the hallmark — not hemarthrosis (except severe Type 3).
  • Labs: PTT often prolonged but can be NORMAL in mild Type 1 (factor VIII may be normal); normal PT; prolonged bleeding time / abnormal PFA-100; low vWF antigen and/or ristocetin cofactor activity; low factor VIII. A normal PTT does not rule out vWD.
  • Type 2N mimics hemophilia A with markedly low factor VIII but is autosomal recessive; Type 2B causes thrombocytopenia.
  • DDAVP releases stored vWF and works well for Type 1; vWF-containing factor VIII concentrates are used for Type 3 and many Type 2 subtypes.
  • DDAVP is contraindicated in Type 2B (gain-of-function vWF–GpIb binding) because it can worsen thrombocytopenia.
  • Aminocaproic acid (Amicar) is an antifibrinolytic useful for mucosal bleeding.
  • Cryoprecipitate contains vWF and factor VIII and can be used in vWD.

Pitfalls

  • Confusing vWD with hemophilia: hemarthrosis and deep muscle hematomas point to hemophilia, whereas vWD causes mucocutaneous bleeding (though Type 2N and severe Type 3 can lower factor VIII enough to mimic hemophilia).
  • Assuming the PTT is always prolonged in vWD — in mild Type 1, factor VIII may remain within the normal range, so the PTT can be normal; a normal PTT does not exclude vWD. PTT prolongation is most reliable in Type 3 and Type 2N.
  • Assuming all Type 2 subtypes are autosomal dominant — 2A, 2B, and 2M are dominant, but 2N is autosomal recessive.
  • Assuming DDAVP works for all types — it is effective in Type 1, unreliable in most Type 2 and Type 3, and specifically contraindicated in Type 2B.
  • Forgetting that DDAVP can precipitate thrombocytopenia in Type 2B by releasing gain-of-function vWF that binds platelet GpIb.
  • Forgetting that when vWD prolongs the PTT it does so via low factor VIII; PT stays normal.
  • Mislabeling the mixing study result — in vWD the prolonged PTT corrects with mixing (deficiency, not inhibitor).
  • Expecting Type 2's vWF antigen to always be low; it may be normal, with the defect being disproportionately reduced function (low activity-to-antigen ratio).
  • Overlooking that Type 3 has markedly decreased factor VIII because absent vWF fails to stabilize it.
  • Assuming platelet count is always normal — Type 2B is the exception with thrombocytopenia.

Clinical pearls

  • Prolonged PTT + normal PT + mucocutaneous bleeding = think von Willebrand disease — but a normal PTT does not rule it out (mild Type 1 may have normal factor VIII).
  • Type 1 is quantity, Type 2 is quality, Type 3 is near-total absence.
  • Type 2N is the autosomal recessive Type 2 subtype that mimics hemophilia A — the rest of Type 2 (2A/2B/2M) is autosomal dominant.
  • DDAVP for Type 1; vWF-containing factor VIII concentrates for Type 3; avoid DDAVP in Type 2B.
  • Low vWF drags factor VIII down with it — explaining the prolonged PTT when it occurs.
  • Ristocetin cofactor activity measures vWF function; antigen measures vWF quantity.
  • Low activity-to-antigen ratio flags a qualitative (Type 2) defect.

Frequently asked

Why is the PTT prolonged in von Willebrand disease if it is primarily a platelet-adhesion problem?

vWF also carries and stabilizes factor VIII. Low or dysfunctional vWF leads to low factor VIII, which prolongs the PTT (PT remains normal). Note that in mild Type 1 vWD, factor VIII can still be within the normal range, so the PTT may be normal — a normal PTT does not exclude vWD.

How do I distinguish von Willebrand disease from hemophilia A on an exam?

Both may prolong PTT with normal PT, but vWD causes mucocutaneous bleeding (epistaxis, menorrhagia, easy bruising) and an abnormal bleeding time/PFA-100, whereas hemophilia A causes hemarthrosis and deep muscle hematomas with an X-linked pattern and normal platelet function. Keep in mind the PTT can be normal in mild Type 1 vWD. Note that Type 2N vWD can mimic hemophilia A but is inherited in an autosomal recessive pattern.

What is the inheritance pattern of the vWD types and subtypes?

Type 1 is autosomal dominant. Among Type 2 subtypes, 2A, 2B, and 2M are autosomal dominant, but 2N is autosomal recessive because it typically requires two abnormal alleles (homozygous or compound heterozygous) to manifest. Type 3 is autosomal recessive.

Which type of vWD responds best to DDAVP, and when is it contraindicated?

Type 1 responds best because DDAVP releases stored vWF from endothelium, which works well for a partial quantitative deficiency. It is unreliable in most Type 2 subtypes and in Type 3 (absent vWF), and it is contraindicated in Type 2B, where releasing gain-of-function vWF can worsen thrombocytopenia.

Why is DDAVP dangerous in Type 2B vWD specifically?

Type 2B has a gain-of-function mutation that increases vWF binding to platelet GpIb. DDAVP releases this abnormal vWF, which binds and clears platelets, precipitating or worsening thrombocytopenia — so it should be avoided rather than simply considered less effective.

What is the difference between a quantitative and a qualitative vWD defect?

Quantitative defects (Types 1 and 3) mean there is too little vWF — partial in Type 1, essentially absent in Type 3. A qualitative defect (Type 2) means the vWF is present but dysfunctional, so function (ristocetin cofactor activity) is disproportionately decreased even if the antigen level is normal or only mildly reduced.

Why is factor VIII markedly decreased in Type 3 vWD?

vWF normally carries and stabilizes factor VIII. In Type 3, vWF is essentially absent, so factor VIII is not stabilized and falls markedly, producing the most severe bleeding phenotype and a reliably prolonged PTT. (Type 2N also lowers factor VIII by impairing its binding site on vWF, and is autosomal recessive.)

What laboratory tests confirm vWD?

Low vWF antigen and/or low vWF activity (ristocetin cofactor), along with low factor VIII. Supporting findings include a prolonged PTT (though it can be normal in mild Type 1), normal PT, and a prolonged bleeding time or abnormal PFA-100. A low activity-to-antigen ratio points to a qualitative (Type 2) defect.

How is Type 3 vWD treated?

With vWF-containing factor VIII concentrates, since DDAVP is inadequate when little to no stored vWF exists. Antifibrinolytics like aminocaproic acid can help with mucosal bleeding.

Does the mixing study correct in vWD?

Yes. When the PTT is prolonged in vWD, it corrects with a 1:1 mix with normal plasma because it reflects a factor deficiency (low factor VIII), not an inhibitor.

Turn this into reasoning you can use on exam day — practice von Willebrand Disease Types on branching cases where your decisions shape the patient.

We value your privacy

HIKMA uses cookies that are strictly necessary to run the app, plus optional cookies for functionality, analytics, and marketing. You decide what we use. See our Cookie Policy and Privacy Policy.